HEALINK

Healink Biopharma is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-value targets within oncology, immunology, and metabolic diseases, utilizing a proprietary structure-based drug design platform. Its clinical pipeline includes HL-001, a RORγt inverse agonist for autoimmune conditions, and HL-007, a selective HPK1 inhibitor for advanced solid tumors. Healink also advances programs targeting URAT1 for gout and KRAS G12C for various malignancies. Backed by leading venture capital firms like Lilly Asia Ventures and 6 Dimensions Capital, the company aims to address significant unmet medical needs through precision medicine.